Immunis, Inc., a private biotech developing innovative cellular secretomes to address age-related diseases and immune dysfunction, shares that its Chief Business Officer, Mark Cabato, CFA will be speaking at the Global Life Science Partnering and Investor Conference (GPIC) in San Diego. GPIC stands as a premier international networking event, uniting top-level executives, financiers, venture capitalists, and business development experts from foremost pharmaceutical and biotech firms.

The conference is a critical platform for fostering collaborations and exploring new opportunities within the life sciences sector. Together, an elite group of industry leaders, investors, and entrepreneurs share insights aimed at addressing some of the most pressing challenges in healthcare today. Mr. Cabato will be among the industry figures presenting Immunis’ innovative secretome therapeutics.

Immunis is excited to share its pre-clinical achievements with its investigational secretome, IMMUNA, in reversing muscle atrophy and improving metabolism. The GPIC stage will undoubtedly provide the opportunity for strategic guidance of Immunis’ business and scientific direction. Mr. Cabato looks forward to engaging with the welcoming community of biotech stakeholders and exploring avenues for mutual growth and collaboration.

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.

Contact email: contact@immunisbiomedical.com